Drug Markets/Deutetrabenazine

Deutetrabenazine

12 NDCs across 1 manufacturer|0 Generic,12 Brand

Deutetrabenazine is used to treat chorea and tardive dyskinesia, per the National Library of Medicine's MED-RT classification.

▸ More about this market

The brand product was first FDA-approved on Apr 3, 2017, and the first generic was approved Dec 26, 2024. In 2024, Medicare Part D spent $1.7 billion on Deutetrabenazine across 245,000 claims for 31,000 beneficiaries.

Deutetrabenazine is available as 12 NDCs from 1 manufacturer (0 generic, 12 brand), with NADAC prices from $83.20 to $502.40 per EA — the most expensive product costs about 6.0× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.

Total NDCs

12

0G / 12B

Manufacturers

1

competing in market

Price Spread

$83.20 – $502.40

per EA

7d Activity

4↑6↓1 flat

avg -0.0% WoW · of 12 NDCs

Market Price Trend

Monthly average NADAC per unit, split by generic and brand.

Explore this market from other angles

Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.

Manufacturer Breakdown

1 manufacturer producing DEUTETRABENAZINE

Drug Portfolio

12 NDCs total, 12 shown

WatchDrug ↕Price 7d Change ↕
AUSTEDO XR 48 MG TABLET
$502.3958
per EA
-0.03%
AUSTEDO XR 42 MG TABLET
$498.7264
per EA
0.00%
AUSTEDO XR 36 MG TABLET
$416.4275
per EA
-0.04%
AUSTEDO XR 30 MG TABLET
$332.6513
per EA
+0.07%
AUSTEDO XR 18 MG TABLET
$251.0206
per EA
-0.06%
AUSTEDO XR 24 MG TABLET
$250.1588
per EA
-0.06%
AUSTEDO XR TITR(12-18-24-30 MG)
$249.3230
per EA
—
AUSTEDO XR 12 MG TABLET
$166.8782
per EA
-0.04%
AUSTEDO 12 MG TABLET
$125.0268
per EA
+0.02%
AUSTEDO 9 MG TABLET
$93.8562
per EA
+0.03%
AUSTEDO XR 6 MG TABLET
$83.2042
per EA
+0.08%
AUSTEDO 6 MG TABLET
$83.2005
per EA
-0.08%

Frequently Asked Questions

What is Deutetrabenazine used to treat?

Deutetrabenazine is used to treat chorea and tardive dyskinesia, per the National Library of Medicine's MED-RT classification.

When did Deutetrabenazine become available as a generic?

FDA approved the first generic Deutetrabenazine (ANDA) on Dec 26, 2024.

How much does Medicare spend on Deutetrabenazine?

In 2024, Medicare Part D spent $1.7 billion on Deutetrabenazine across 245,000 claims for 31,000 beneficiaries.

How many Deutetrabenazine products are on the market?

The Deutetrabenazine drug market contains 12 NDCs from 1 manufacturer — 0 generic and 12 brand products.

What is the price range for Deutetrabenazine?

NADAC reference prices for Deutetrabenazine range from $83.2005 to $502.3958 per EA — the most expensive product costs about 6.0× the cheapest.

Which manufacturers make Deutetrabenazine?

1 manufacturer lists Deutetrabenazine in NADAC. Ranked by number of NDCs, the largest are Teva Neuroscience, Inc. (12).

How has the price of Deutetrabenazine changed recently?

Over the past 7 days, 4 Deutetrabenazine NDCs rose and 6 fell, with a market-wide average change of -0.0%.